SavedAdd your journal

Journals / Türk Patoloji Dergisi / 2014 / Cilt: 30 - Sayı: 2

Primer Meme Kanserinde Lenfatik Vaskülarizasyon: HER2 Overekspresyonu Gösteren Tümörler; Steroid Reseptör-Pozitif, Triple-Pozitif ve Triple-Negatif Tümörlere Kıyasla Daha Fazla Lenfatik Damar İçermektedir

Lymphatic Vascularization in Primary Breast Cancer: HER2 Overexpressing Tumors Contain More Lymphatics than Steroid Receptor Positive, Triple-Positive and Triple Negative Breast Carcinomas

Savelina POPOVSKA
Ivan IVANOV
Pages
124–132
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: The median intra-tumor lymphatic vascular density and the median intra-tumor relative lymphatic vascular area were found to differ significantly among the studied groups of breast cancer (KW =49.8611; p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to examine the relationship between the immunohistochemical subtypes of invasive breast cancer and lymphatic vascularization.
📊
Key Findings & Data:Material and Method: One hundred and seventy nine cases of randomly selected invasive breast cancer patients, surgically treated between 2004 and 2007, were retrospectively studied.
💡
Conclusion & Impact:Results: The median intra-tumor lymphatic vascular density and the median intra-tumor relative lymphatic vascular area were found to differ significantly among the studied groups of breast cancer (KW =49.8611; p
🔬Design:Research Article
📍Scope:2004 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to examine the relationship between the immunohistochemical subtypes of invasive breast cancer and lymphatic vascularization. Material and Method: One hundred and seventy nine cases of randomly selected invasive breast cancer patients, surgically treated between 2004 and 2007, were retrospectively studied. These were classified into steroid receptor positive (steroid receptor positive/ HER2 negative), triple positive (steroid receptor and HER2 positive), triple negative (steroid receptor and HER2 negative) and HER2 overexpressing (steroid receptor negative /HER2 positive) carcinomas. Appropriate immunostaining and in-situ hybridization techniques were applied and results were statistically analyzed. Results: The median intra-tumor lymphatic vascular density and the median intra-tumor relative lymphatic vascular area were found to differ significantly among the studied groups of breast cancer (KW =49.8611; p

Özet

Amaç: Bu çalışmada, meme kanserlerinin immünhistokimyasal alt tipleri ile lenfatik vaskülarizasyon arasındaki ilişkinin saptanması amaçlanmıştır. Gereç ve Yöntem: Çalışmaya 2004-2007 yılları arasında opere edilmiş, rastlantısal olarak seçilen 179 invaziv meme kanserli hasta alındı. Hastalar, steroid reseptör pozitif (steroid reseptör pozitif/ HER2 negatif), triple pozitif (steroid reseptör pozitif ve HER2 pozitif), triple negatif (steroid reseptör ve HER2 negatif) ve HER2 aşırı ekspresyonlu (steroid reseptör negatif ve HER2 pozitif) olarak 4 alt tipte sınıflandı. Olgularda gerekli immünhistokimyasal ve in situ hibridizasyon incelemeler yapılarak, bulgular istatistiksel olarak değerlendirildi. Bulgular: Ortanca intratümöral lenfatik damar yoğunluğu ve ortanca intratümör lenfatik damar alanı, alt tipler arasında anlamlı olarak değişkenlik gösterdi (KW =49.8611; p

🔖

Cite This Article

POPOVSKA, S., IVANOV, I. (2022). Primer Meme Kanserinde Lenfatik Vaskülarizasyon: HER2 Overekspresyonu Gösteren Tümörler; Steroid Reseptör-Pozitif, Triple-Pozitif ve Triple-Negatif Tümörlere Kıyasla Daha Fazla Lenfatik Damar İçermektedir. Türk Patoloji Dergisi, Cilt: 30 - Sayı: 2, 124–132. https://ajindex.com/articles/655205

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Bhargava R, Beriwal S, Striebel JM, Dabbs DJ. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR. Appl Immunohistochem Mol Morphol. 2010;18:113-8
  2. Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A. Breast cancer classification according to immunohistochemical markers: Clinicopathologic features and short-term survival analysis in a population-based study from the south of Switzerland. Ann Oncol. 2009;20:628-35
  3. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MCU, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA. 2006;295:2492-502
  4. Yu Q, Niu Y, Liu N, Zhang JZ, Liu TJ, Zhang RJ, Wang SL, Ding XM, Xiao XQ. Expression of androgen receptor in breast cancer and its significance as a prognostic factor. Ann Oncol. 2011;22:1288-94
  5. Cheang MCU, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368
  6. Laakso M, Tanner M, Nilsson J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmstrom P, Wilking N, Bergh J, Isola J. Basoluminal carcinoma: A new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res. 2006;12:4185-91
  7. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO. Triple-negative breast cancer: Distinguishing between basal and nonbasal subtypes. Clin Cancer Res. 2009; 15:2302-10
  8. Hasebe T, Iwasaki M, Akashi-Tanaka S, Hojo T, Shibata T, Kinoshita T, Tsuda H. Important histologic outcome predictors for patients with invasive ductal carcinoma of the breast. Am J Surg Pathol. 2011;35:1484-97
  9. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: Comparison of clinicopathologic features and survival. Clinical Medicine & Research. 2009;7:(1-2)4-13
  10. Blackwell KL, Dewhirst MW, Liotcheva V, Snyder S, Broadwater G, Bentley R, Lal A, Riggins G, Anderson S, Vredenburgh J, Proia A, Harris LN. HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxi